Publications by authors named "Natalia Merker"

Article Synopsis
  • - The rise in azole-resistant invasive aspergillosis (IA) in hematological patients necessitates effective molecular methods for detecting resistance mutations from clinical samples, as positive cultures are uncommon in this patient group.
  • - The study compared an in-house polymerase chain reaction (PCR) method, targeting specific resistance mutations, to the commercially available AsperGenius® real-time PCR system using various clinical samples from immunocompromised patients.
  • - Results indicated that the in-house PCR assays had higher sensitivity for detecting resistance in bronchoalveolar lavage (BAL) and biopsy samples; however, AsperGenius® offered quicker results, highlighting the benefits of molecular detection over culture-based methods.
View Article and Find Full Text PDF

As the incidence of azole resistance in Aspergillus fumigatus is rising and the diagnosis of invasive aspergillosis (IA) in immunocompromised patients is rarely based on positive culture yield, we screened our Aspergillus DNA sample collection for the occurrence of azole resistance mediating cyp51 A key mutations. Using two established, a modified and a novel polymerase chain reaction (PCR) assays followed by DNA sequence analysis to detect the most frequent mutations in the A. fumigatus cyp51 A gene conferring azole resistance (TR34 (tandem repeat), L98H and M220 alterations).

View Article and Find Full Text PDF

The increasing incidence of azole resistance in Aspergillus fumigatus causing invasive aspergillosis (IA) in immunocompromised/hematological patients emphasizes the need to improve the detection of resistance-mediating cyp51A gene mutations from primary clinical samples, particularly as the diagnosis of invasive aspergillosis is rarely based on a positive culture yield in this group of patients. We generated primers from the unique sequence of the Aspergillus fumigatus cyp51A gene to establish PCR assays with consecutive DNA sequence analysis to detect and identify the A. fumigatus cyp51A tandem repeat (TR) mutation in the promoter region and the L98H and M220 alterations directly in clinical samples.

View Article and Find Full Text PDF